Scalp psoriasis: An overview of the disease and available therapies

Journal of Drugs in Dermatology

Volumn 9, Issue 8, 2010, Pages 912-918

  Crowley, Jeffrey ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; FLUOCINOLONE ACETONIDE; INFLIXIMAB; METHOTREXATE; MOMETASONE FUROATE; TACALCITOL; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; TRIAMCINOLONE HEXACETONIDE; DRUG DERIVATIVE; GLUCOCORTICOID; VITAMIN D;

ALOPECIA; BURNING SENSATION; CHEILITIS; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; DISEASE SEVERITY; DRUG EFFICACY; DRY SKIN; EPISTAXIS; GASTROINTESTINAL SYMPTOM; GRENZ RADIATION; HIRSUTISM; HISTOPATHOLOGY; HUMAN; HYPERTENSION; LIVER TOXICITY; MALAISE; NAUSEA; NEPHROTOXICITY; PATIENT COMPLIANCE; PHOTOTHERAPY; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; QUALITY OF LIFE; REVIEW; SCALP; SCALP PSORIASIS; SIDE EFFECT; SKIN REDNESS; SYMPTOM; TRIACYLGLYCEROL BLOOD LEVEL; HOSPITALIZATION; INTRADERMAL DRUG ADMINISTRATION; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY;

ADMINISTRATION, CUTANEOUS; GLUCOCORTICOIDS; HUMANS; MEDICATION ADHERENCE; PHOTOTHERAPY; PSORIASIS; QUALITY OF LIFE; SCALP; SEVERITY OF ILLNESS INDEX; VITAMIN D;

EID: 77955892955     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:121-128. (Pubitemid 38832741)
2. Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004. J Am Acad Dermatol. 2008;60:218-224.
3. Farber EM, Nall L. Natural history and treatment of scalp psoriasis. Cutis. 1992;49:396-400.
4. Van de Kerkhof PC, De Hoop D, De Korte J, Kuipers MV. Scalp psoriasis, clinical presentations and therapeutic management. Dermatology. 1998;197:326-334. (Pubitemid 29000784)
5. Van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2:159-165.
6. Elewski BE. Clinical diagnosis of common scalp disorders. J Invest Dermatol Symp Proc. 2005;10:190-193.
7. Gupta AK, Batra R, Bluhm R, et al. Skin diseases associated with Malassezia species. J Am Acad Dermatol. 2004;51:785-798. (Pubitemid 39516896)
8. Karason A, Gudjonsson JE, Jonsson HH, et al. Genetics of psoriasis in Iceland: Evidence for linkage of subphenotypes to distinct loci. J Invest Dermatol. 2005;124:1177-1185. (Pubitemid 40847404)
9. Wozel G. Psoriasis treatment in difficult locations: Scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26:448-459.
10. Woo SM, Choi JW, Yoon HS, et al. Classification of facial psoriasis based on the distributions of facial lesions. J Am Acad Dermatol. 2008;58:959-963.
11. Chen SC, Yeung J, Chren MM. Scalpdex: A quality-of-life instrument for scalp dermatitis. Arch Dermatol. 2002;138:803-807. (Pubitemid 34625526)
12. Amatya B, Wennersten G, Nordlind K. Patients' perspective of pruritus in chronic plaque psoriasis: A questionnaire-based study. J Eur Acad Dermatol Venereol. 2008;22:822-826. (Pubitemid 351837116)
13. Bardazzi F, Fanti PA, Orlandi C, et al. Psoriatic scarring alopecia: Observations in four patients. Int J Dermatol. 1999;38:765-768. (Pubitemid 29515478)
14. Cockayne SE, Messenger AG. Familial scarring alopecia associated with scalp psoriasis. Br J Dermatol. 2001;144:425-427. (Pubitemid 32178839)
15. Runne U, Kroneisen-Wiersma P. Psoriatic alopecia: Acute and chronic hair loss in 47 patients with scalp psoriasis. Dermatology. 1992;185:82-87.
16. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: An overview. Am Fam Physician. 2006;74:125-130. (Pubitemid 44049740)
17. Werner B, Brenner FM, Boer A. Histopathologic study of scalp psoriasis: Peculiar features including sebaceous gland atrophy. Am J Dermatopathol. 2008;30:93-100. (Pubitemid 351441978)
18. Headington JT, Gupta AK, Goldfarb MT, et al. A morphometric and histologic study of the scalp in psoriasis. Paradoxical sebaceous gland atrophy and decreased hair shaft diameters without alopecia. Arch Dermatol. 1989;125:639-642. (Pubitemid 19129069)
19. Rosina P, Zamperetti MR, Giovannini A, Girolomoni G. Videocapillaroscopy in the differential diagnosis between psoriasis and seborrheic dermatitis of the scalp. Dermatology. 2007;214:21-24. (Pubitemid 46032996)
20. Ross EK, Vincenzi C, Tosti A. Videodermoscopy in the evaluation of hair and scalp disorders. J Am Acad Dermatol. 2006;55:799-806. (Pubitemid 44556832)
21. Thaci D, Daiber W, Boehncke WH, Kaufmann R. Calcipotriol solution for the treatment of scalp psoriasis: Evaluation of efficacy, safety and acceptance in 3,396 patients. Dermatology. 2001;203:153-156. (Pubitemid 34701576)
22. Krell J, Nelson C, Spencer L, Miller S. An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. J Am Acad Dermatol. 2008;58:609-616.
23. Krell J, Chen Y, Caro I. Response of head and neck psoriasis to efalizumab: A pooled data analysis. Presented at: Summer Meeting of the American Academy of Dermatology; July 30-August 3, 2008; Chicago, IL. Poster 2407.
24. Reygagne P, Mrowietz U, Decroix J, et al. Clobetasol propionate shampoo 0.05% and calcipotriol solution 0.005%: A randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat. 2005;16:31-36. (Pubitemid 40283322)
25. Krueger GG. New method being developed for assessing psoriasis. National Psoriasis Foundation Forum. 1999;5:4-5.
26. Heydendael VM, De Borgie CA, Spuls PI, et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9:131-135. (Pubitemid 38457270)
27. Johnson LA. P.O.W.E.R. (Providing Outcomes With Effective Results) in the shower - A patient experience program examining scalp psoriasis treatments. Presented at: 65th Annual Meeting of the American Academy of Dermatology; February 2-6, 2007; Washington, DC. Poster 2755.
28. Warren RB, Brown BC, Griffiths CE. Topical treatments for scalp psoriasis. Drugs. 2008;68:2293-2302.
29. Gupta SN, Taylor CR. 308-nm excimer laser for the treatment of scalp psoriasis. Arch Dermatol. 2004;140:518-520. (Pubitemid 38668955)
30. Taneja A, Racette A, Gourgouliatos Z, Taylor CR. Broad-band UVB fiber-optic comb for the treatment of scalp psoriasis: A pilot study. Int J Dermatol. 2004;43:462-467. (Pubitemid 38868259)
31. Johannesson A, Lindelof B. Additional effect of Grenz rays on psoriasis lesions of the scalp treated with topical corticosteroids. Dermatologica. 1987;175:290-292. (Pubitemid 17163973)
32. Lindelof B, Johannesson A. Psoriasis of the scalp treated with Grenz rays or topical corticosteroid combined with Grenz rays. A comparative randomized trial. Br J Dermatol. 1988;119:241-244.
33. Van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197:31-36. (Pubitemid 28327834)
34. Andreassi L, Giannetti A, Milani M. Efficacy of betamethasone valerate mousse in comparison with standard therapies on scalp psoriasis: An open, multicentre, randomized, controlled, cross-over study on 241 patients. Br J Dermatol. 2003;148:134-138. (Pubitemid 36114874)
35. Green C, Ganpule M, Harris D, et al. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol. 1994;130:483-487. (Pubitemid 24204668)
36. Jemec GB, Ganslandt C, Ortonne JP, et al. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol. 2008;59:455-463.
37. Buckley C, Hoffmann V, Shapiro J, et al. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology. 2008;217:107-113.
38. Mazzotta A, Esposito M, Carboni I, et al. Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat. 2007;18:84-87. (Pubitemid 46801840)
39. Griffiths CE, Finlay AY, Fleming CJ, et al. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat. 2006;17:90-95.
40. Burns D, Breathnach S, Cox N, Griffiths CE. Rook's Textbook of Dermatology. 7th ed. Malden, MA: Blackwell Publishing. 2004.
41. Feldman SR, Housman TS. Patients' vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-224. (Pubitemid 36506427)
42. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: An assessment of the benefits and risks. Br J Dermatol. 2005;152:597-615. (Pubitemid 40571289)
43. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum. 1994;37:316-328. (Pubitemid 24093622)
44. Roenigk HH Jr, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: Consensus conference. J Am Acad Dermatol. 1998;38:478-485. (Pubitemid 28125534)
45. Behnam SM, Behnam SE, Koo JY. Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. J Drugs Dermatol. 2005;4:189-194.
46. Neoral® (cyclosporine) [Prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation. August 2005.
47. Griffiths CE, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: An international consensus statement. Br J Dermatol. 2004;150(Suppl 67):11-23. (Pubitemid 38903574)
48. Carlin CS, Callis KP, Krueger GG. Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol. 2003;139:436-442. (Pubitemid 36427607)
49. Soriatane® (acitretin) [Prescribing information]. Palo Alto, CA: Connetics Corporation; July 2004.
50. Takahashi D, Oliveira M, Vera Paramo A, Stengel FM. Efficacy and safety of efalizumab for scalp psoriasis: Results from a prospective, 24-week, open-label phase IIIb/IV clinical trial in patients from Latin America. Presented at: 66th Annual Meeting of the American Academy of Dermatology; February 1-5, 2008; San Antonio, TX. Poster 2674.
51. Kircik L, Caro I, Schlessinger J, Chen Y. A phase IV randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of efalizumab in patients with moderate to severe plaque psoriasis involving the scalp. Presented at: Annual Meeting of the American Academy of Dermatology; March 6-10, 2009; San Francisco, CA. Poster P3380.
52. Menter A, Reich K, Li S, Guzzo C. Consistency of infliximab response in different body regions for treatment of moderate to severe psoriasis: Results from controlled clinical trials. Presented at the Annual Meeting of the American Academy of Dermatology, February 1-5, 2008; San Antonio, TX. Poster P2607.
53. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598-603. (Pubitemid 46400183)
54. Moderate to severe plaque psoriasis with scalp involvement. www.clinicaltrials.gov. Clinical Trial Identifier: NCT00791765.
55. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: A paradoxical adverse reaction. Arthritis Rheum. 2005;52:2513-2518. (Pubitemid 41117439)
56. Papadavid E, Gazi S, Dalamaga M, et al. Palmoplantar and scalp psoriasis occurring during anti-tumour necrosis factor-alpha therapy: A case series of four patients and guidelines for management. J Eur Acad Dermatol Venereol. 2008;22:380-382. (Pubitemid 351247441)
57. De Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-alpha inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223-231. (Pubitemid 46294587)
58. Nestle FO, Gilliet M. Defining upstream elements of psoriasis pathogenesis: An emerging role for interferon alpha. J Invest Dermatol. 2005;125:xiv-xxv.